ADMA Biologics Statement on Tariffs

Core Viewpoint - ADMA Biologics, Inc. emphasizes its strategic advantage due to fully U.S.-based manufacturing and supply chain operations, which are insulated from recent tariffs on foreign goods [1][2]. Group 1: Company Overview - ADMA Biologics is a biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM®, and NABI-HB®, targeting immune deficiencies and hepatitis B [3]. - ADMA operates an FDA-licensed facility in Boca Raton, Florida, for the production of its immune globulin products and also runs FDA-approved source plasma collection through its subsidiary, ADMA BioCenters [3]. Group 2: Strategic Positioning - The company asserts that the tariffs on foreign goods will not affect its supply chain or production operations due to its fully integrated U.S.-based supply chain [2]. - ADMA's operational model ensures enhanced supply chain robustness, resilience, and regulatory compliance, aligning with federal and private sector preferences for U.S.-made products [2]. - By maintaining complete operational control within the U.S., ADMA is positioned to leverage national economic incentives and provide reliable, high-quality offerings to its domestic customers [2].